Arcturus Therapeutics Presents ARCT-810 Phase 2 Data

What Happened
Arcturus Therapeutics Holdings, Inc. (ARCT) announced on September 23, 2026 that it presented an overview of Phase 2 clinical data for ARCT-810 and provided an update on its mRNA delivery platform. The company issued a press release summarizing the presentation; both the Presentation and the Press Release are furnished as exhibits to the 8-K.

Key Details

• Filing date: September 23, 2026 (Item 7.01, Regulation FD Disclosure).
• Topic: ARCT-810 Phase 2 clinical data and an update on the company’s mRNA delivery platform.
• Materials furnished as exhibits: Presentation (Exhibit 99.1) and Press Release (Exhibit 99.2).
• The disclosure was furnished under Regulation FD and does not itself report financial results or executive changes.

Why It Matters
The disclosed Phase 2 data and platform update are material to assessing Arcturus’s clinical progress and technology capabilities. Retail investors should review the furnished Presentation and Press Release to evaluate the specifics of the clinical results, any stated next steps or timelines, and potential implications for the company’s development milestones and partnerships.